微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2017, Vol. 9 ›› Issue (2): 142-145.doi: 10.3969/j.issn.1674-5671.2017.02.12

• 临床研究 • 上一篇    下一篇

恩度同步放疗治疗不能手术局部晚期老年非小细胞肺癌的临床疗效

  

  1. 福建医科大学临床教学医院 福州肺科医院肿瘤科
  • 出版日期:2017-04-25 发布日期:2017-06-12
  • 通讯作者: 陈群 chenqun88@qq.com
  • 基金资助:

    福州市科技计划资助项目（2012-S-156-5）

Preliminary study of recombinant human endostatin (Endostar) combined with concurrent intensity-modulated radiation therapy for inoperable local advanced non-small cell lung cancer in elderly patients

  • Online:2017-04-25 Published:2017-06-12

赞

被引次数

1

摘要：

目的 观察重组人血管内皮抑制素（恩度）同步放疗治疗不能手术的局部晚期老年非小细胞肺癌的疗效和不良反应。方法 将40例不能手术的老年局部晚期非小细胞肺癌患者随机分为恩度联合放疗组（联合组）和单纯放疗组（放疗组），每组20例。联合组采用恩度15 mg/d，d1～14连续输注，21 d为一个周期；同时行调强放疗，放疗采用常规分割，原发灶及纵隔淋巴结放疗剂量为60～66 Gy/30～33次，6～7周。放疗组仅接受调强放疗，剂量、分割方式同联合组。观察两组患者近期疗效、临床获益率、疾病进展时间和总生存时间。结果 联合组和放疗组有效率分别为75.0%和80.0%，疾病控制率分别为100%和90.0%；中位无疾病进展时间（mPFS）分别为9.4个月和 6.8个月，中位生存时间（mOS）分别为 17.5个月和 14.1个月，两组差异均无统计学意义（Ｐ＞0.05）。两组主要不良反应多为0~2级，差异无统计学意义（Ｐ＞0.05）。结论 恩度联合放疗治疗不能手术的老年局部晚期非小细胞肺癌中位生存时间有延长趋势，且不良反应未增加，有一定临床指导意义。

关键词: 肺肿瘤, 不可手术, 局部晚期, 老年, 重组人血管内皮抑制素, 调强放疗, 疗效

Abstract:

Objective To observe the efficacy and safety of recombinant human endostatin（Endostar） combined with concurrent intensity-modulated radiation therapy （IMRT） for inoperable local advanced non-small cell lung cancer （NSCLC） in elderly patients. Methods A total of 40 elderly patients with inoperable local advanced NSCLC confirmed by pathology were randomly divided into a control group and trial group，each with 20 cases. Patients in the trial group received IMRT，and the dosage for primary tumor and mediastinal lymph node metastasis was DT 60-66 Gy，30-33 measurement unit for 6-7 weeks；in addition，these patients concurrently received 15 mg Endostar by intravenous drip once per day for 14 days. Control patients received IMRT alone，using the same method and dosage as in the trial group. Efficacy and survival were compared between the two patient groups. Results The trial and control groups showed no significant difference between ORR （75.0% vs 80.0%，P=0.326），DCR（100% vs 90.0%，P=0.031），mPFS （9.4 vs 6.8 months，P=0.286） or mOS （17.5 vs 14.1 months，P=0.052）. The two groups experienced similar major toxic effects，most of which were G1/2. Conclusion Endostar combined with concurrent IMRT showed a tendency toward longer median survival than IMRT alone for treating inoperable local advanced NSCLC in elderly patients.

Key words: Lung neoplasms, Inoperable, Local advanced, Elderly, Recombinant human endostatin, Intensity-modulated radiation therapy, Efficacy